You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (6) |
Back to Search
Doxorubicin and imatinib co-loaded pegylated nanostructured carriers to effectively overcome doxorubicin resistance in metastatic tumors
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-FDP-036
- By: YONG, Chul Soon (Yeungnam University, Gyeongsan-Si, Korea, Republic Of)
- Co-author(s): Jae Hee Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
Biki Gupta: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
Shiva Pathak: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
Raj Kumar Thapa: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
Jee-Heon Jeong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
Dong Shik Kim: Hanyang University, Ansan-si, Korea, Republic Of
Han-Gon Choi: Hanyang University, Ansan-si, Korea, Republic Of
Chul Soon Yong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
Jong Oh Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of - Abstract:
Background
Resistance to chemotherapeutic agents is viewed as a major impediment to successful treatment of metastatic cancers. Doxorubicin(DOX) is often associated with recurrence or metastasis of cancers, primarily as a result of development of multidrug resistance(MDR).Purpose
The purpose was to prepare PEGylated-nanostructured platforms for.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026